ELAIN indicates Early vs Late Initiation of Renal Replacement Therapy in Critically Ill Patients With Acute Kidney Injury; KDIGO, Kidney Disease: Improving Global Outcomes; RRT, renal replacement therapy; CKD, chronic kidney disease; GFR, glomerular filtration rate; AKI, acute kidney injury; SOFA, sepsis-related organ failure assessment; NGAL, neutrophil gelatinase–associated lipocalin.
KDIGO indicates Kidney Disease: Improving Global Outcomes. In the delayed group, 18 patients had an absolute indication for RRT. The median (quartile 1 [Q1], quartile 3 [Q3]) duration of follow-up was 90 days (Q1, Q3: 90, 90) in the early group and 90 days (Q1, Q3: 90, 90) in the delayed group. The vertical ticks indicate censored cases.
Trial Protocol and Statistical Analysis
eTable 1. Advanced Inclusion Criteria for Dialysis Initiation
eTable 2. Subgroup Analysis of Patients Assigned to the Delayed Group
eTable 3. Characteristics of Renal Replacement Therapy
eTable 4. Analysis of Pro- and Anti-inflammatory Markers
eTable 5. Cox Regression Analysis of Cytokines
Customize your JAMA Network experience by selecting one or more topics from the list below.
Zarbock A, Kellum JA, Schmidt C, et al. Effect of Early vs Delayed Initiation of Renal Replacement Therapy on Mortality in Critically Ill Patients With Acute Kidney InjuryThe ELAIN Randomized Clinical Trial. JAMA. 2016;315(20):2190–2199. doi:10.1001/jama.2016.5828
Copyright 2016 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
Optimal timing of initiation of renal replacement therapy (RRT) for severe acute kidney injury (AKI) but without life-threatening indications is still unknown.
To determine whether early initiation of RRT in patients who are critically ill with AKI reduces 90-day all-cause mortality.
Design, Setting, and Participants
Single-center randomized clinical trial of 231 critically ill patients with AKI Kidney Disease: Improving Global Outcomes (KDIGO) stage 2 (≥2 times baseline or urinary output <0.5 mL/kg/h for ≥12 hours) and plasma neutrophil gelatinase–associated lipocalin level higher than 150 ng/mL enrolled between August 2013 and June 2015 from a university hospital in Germany.
Early (within 8 hours of diagnosis of KDIGO stage 2; n = 112) or delayed (within 12 hours of stage 3 AKI or no initiation; n = 119) initiation of RRT.
Main Outcomes and Measures
The primary end point was mortality at 90 days after randomization. Secondary end points included 28- and 60-day mortality, clinical evidence of organ dysfunction, recovery of renal function, requirement of RRT after day 90, duration of renal support, and intensive care unit (ICU) and hospital length of stay.
Among 231 patients (mean age, 67 years; men, 146 [63.2%]), all patients in the early group (n = 112) and 108 of 119 patients (90.8%) in the delayed group received RRT. All patients completed follow-up at 90 days. Median time (Q1, Q3) from meeting full eligibility criteria to RRT initiation was significantly shorter in the early group (6.0 hours [Q1, Q3: 4.0, 7.0]) than in the delayed group (25.5 h [Q1, Q3: 18.8, 40.3]; difference, −21.0 [95% CI, −24.0 to −18.0]; P < .001). Early initiation of RRT significantly reduced 90-day mortality (44 of 112 patients [39.3%]) compared with delayed initiation of RRT (65 of 119 patients [54.7%]; hazard ratio [HR], 0.66 [95% CI, 0.45 to 0.97]; difference, −15.4% [95% CI, −28.1% to −2.6%]; P = .03). More patients in the early group recovered renal function by day 90 (60 of 112 patients [53.6%] in the early group vs 46 of 119 patients [38.7%] in the delayed group; odds ratio [OR], 0.55 [95% CI, 0.32 to 0. 93]; difference, 14.9% [95% CI, 2.2% to 27.6%]; P = .02). Duration of RRT and length of hospital stay were significantly shorter in the early group than in the delayed group (RRT: 9 days [Q1, Q3: 4, 44] in the early group vs 25 days [Q1, Q3: 7, >90] in the delayed group; P = .04; HR, 0.69 [95% CI, 0.48 to 1.00]; difference, −18 days [95% CI, −41 to 4]; hospital stay: 51 days [Q1, Q3: 31, 74] in the early group vs 82 days [Q1, Q3: 67, >90] in the delayed group; P < .001; HR, 0.34 [95% CI, 0.22 to 0.52]; difference, −37 days [95% CI, −∞ to −19.5]), but there was no significant effect on requirement of RRT after day 90, organ dysfunction, and length of ICU stay.
Conclusions and Relevance
Among critically ill patients with AKI, early RRT compared with delayed initiation of RRT reduced mortality over the first 90 days. Further multicenter trials of this intervention are warranted.
German Clinical Trial Registry Identifier: DRKS00004367
Acute kidney injury (AKI) is a well-recognized complication of critical illness with a large effect on morbidity and mortality.1 Despite increases in our knowledge of the management of patients who are critically ill, mortality associated with AKI remains high.2-4 Although renal replacement therapy (RRT) provokes a considerable escalation in the complexity of treatment, the optimal timing of initiation of RRT in critically ill patients with AKI is still unknown.5,6 Although the need for RRT in patients with severe AKI and life-threatening complications is unequivocal, the timing of RRT initiation in patients with severe AKI without such complications has not yet been defined. Quiz Ref IDEarlier initiation of RRT may produce benefits by avoiding hypervolemia, eliminating of toxins, establishing acid-base homeostasis, and preventing other complications attributable to AKI. However, early initiation of RRT may unnecessarily expose some patients to potential harm because some patients will spontaneously recover renal function.
The optimal timing of RRT initiation has been the focus of several studies. Current evidence suggests reduced mortality and better renal recovery with earlier RRT initiation.7-9 A recently published pilot multicenter randomized trial investigated the optimal timing of initiation of RRT in critically ill patients with AKI.10 The authors demonstrated the feasibility of conducting a large definitive trial comparing 2 strategies for RRT initiation among critically ill patients with AKI. In this pilot trial, mortality rates were not different between groups.10 Thus, a large randomized study with a robust and relevant clinical end point is warranted to resolve this issue. As an initial step to achieve this goal, a single-center randomized clinical trial was performed to investigate whether early initiation of RRT could reduce 90-day all-cause mortality and to analyze other relevant clinical outcomes of RRT in critically ill patients with AKI.
A randomized, single-center, 2-group, parallel-group trial of different RRT-implementation strategies for critically ill patients with AKI was conducted between August 2013 and July 2015 (trial protocol in Supplement 1). Institutional review board approval was obtained from the research ethics committee of the Chamber of Physicians Westfalen-Lippe and the Westphalian Wilhelms University Muenster and the trial was registered in the German Clinical Trials Register (DRKS00004367). The study was conducted in accordance with the Declaration of Helsinki, October 2008 (49th General Assembly of the World Medical Association). All consent procedures followed local requirements, as approved by the ethics committee of the University of Muenster. The treating investigator informed the patient about the nature of the trial, its aims, and expected advantages, as well as possible risks. Written informed consent was obtained from eligible patients or by their legally authorized representative. Deferred consent was used in emergencies, and a consultant physician independent of the investigational team gave authorization. Once the participant regained capacity or the legally authorized representative was available, the individual was asked to affirm or withdraw consent.
AKI was diagnosed based on changes in the serum creatinine, urine output, or both. Creatinine measurements were performed twice per day. Every patient had a urinary catheter and urine output was measured every hour. Prior to randomization, investigators obtained consent for participation in the study. Assuming all inclusion criteria were fulfilled and no exclusion criteria were met, each patient received a study identification number and treatment allocation at enrollment. Inclusion criteria were (1) Kidney Disease: Improving Global Outcomes (KDIGO) stage 2 (2-fold increase in serum-creatinine from baseline [for baseline serum creatinine, we used the serum creatinine at hospital admission, the last available serum creatinine within the last 3 months, or an estimated serum creatinine as per the KDIGO guideline5 in patients with no information about their prior kidney function] or urinary output <0.5 mL/kg/h for ≥12 hours) despite optimal resuscitation (optimizing intravascular volume [fluid resuscitation: pulmonary artery occlusion pressure/central venous pressure of >12 mm Hg, stroke volume variation <12% in ventilated patients]; optimization of cardiac index [>2.6 L/min/m2]; hemodynamic optimization [mean arterial pressure >65 mm Hg]; normalizing intra-abdominal pressure [<15 mm Hg]); (2) plasma neutrophil gelatinase–associated lipocalin (NGAL) >150 ng/mL; (3) at least 1 of the following conditions: severe sepsis, use of vasopressors or catecholamines (norepinephrine or epinephrine >0.1 µg/kg/min), refractory fluid overload (worsening pulmonary edema, Pao2/FiO2 <300 mm Hg or fluid balance >10% of body weight), development or progression of nonrenal organ dysfunction (Sequential Organ Failure Assessment [SOFA] score ≥2); (4) aged between 18 and 90 years; and (5) intention to provide full intensive care treatment for at least 3 days. Patients with preexisting chronic kidney disease (estimated glomerular filtration rate [GFR] <30 mL/min), previous renal replacement therapy, AKI caused by permanent occlusion or surgical lesion of the renal artery, glomerulonephritis, interstitial nephritis, vasculitis, postrenal obstruction, or hemolytic uremic syndrome or thrombotic thrombocytopenic purpura were excluded. We also excluded patients for pregnancy, prior kidney transplantation, hepatorenal syndrome, AIDS with a CD4 count of <0.05 × 10 E/L, hematologic malignancy with neutrophils of <0.05 × 10 E/L, or participation in another interventional clinical trial.
Patients were randomized in a 1:1 ratio to 1 of the 2 treatment groups using a computerized system. Randomization was stratified by SOFA Cardiovascular score (0-2 vs 3-4) and by the presence or absence of oliguria. A block randomization within each stratum with block size of 10 was used. Early RRT was initiated within 8 hours of diagnosis of stage 2 AKI using the KDIGO classification (urine output <0.5 mL/kg/h for ≥12h or 2-fold increase in serum creatinine compared with baseline). Delayed RRT was initiated within 12 hours of stage 3 AKI (urine output <0.3 mL/kg/h for ≥24 h and/or >3 fold increase in serum creatinine level compared with baseline or serum creatinine of ≥4 mg/dL with an acute increase of at least 0.5 mg/dL within 48 hours [to convert to μmol/L, multiply by 88.4]) or if any of the following absolute indications for RRT were present: serum urea level higher than 100 mg/dL; serum potassium level higher than 6 mEq/L and/or with electrocardiography abnormalities; serum magnesium level higher than 8 mEq/L (to convert to mmol/L, multiply by 0.5); urine production lower than 200 mL per 12 hours or anuria (according to the KDIGO recommendations); and organ edema in the presence of AKI resistant to diuretic treatment (1 attempt with loop diuretics prior to randomization).
Quiz Ref IDOnce RRT was initiated, identical settings were used in both treatment groups according to the KDIGO guidelines. To ensure uniformity of treatment between early and delayed RRT groups, specific protocols for the performance of RRT were strictly adhered to. All patients in both groups were treated using continuous venovenous hemodiafiltration. Replacement fluid was delivered into extracorporal circuit before the filter (ie, predilution), with a ratio of dialysate to replacement fluid of 1:1. The effluent flow prescribed was based on the patient’s body weight at the time of randomization and was 30 mL/kg/h (additional fluid removal without replacement was not considered part of the prescribed dose). Blood flow was kept above 110 mL/min. The delivered dose of RRT was monitored based on bloodside urea kinetics. Regional anticoagulation with citrate was used to prevent circuit clotting. RRT was discontinued if renal recovery defined by urine output (>400 mL/24 h without and 2100 mL/24 h with diuretic treatment) and creatinine clearance (>20 mL/min) occurred. If cessation criteria were not fulfilled after 7 days, continuous renal replacement therapy could be changed to an intermittent procedure (sustained low-efficiency daily dialysis [SLEDD], slow continuous ultrafiltration or intermittent hemodialysis).
Following randomization, laboratory and physiologic data, severity of illness as measured by the modified SOFA score, and RRT administration details for 21 days were documented. All patients were followed up for 90 days to ascertain vital status, RRT requirement, and recovery of renal function.
The primary end point was overall mortality in a 90-day follow-up period (from randomization). Secondary outcomes included overall mortality in a 28- and 60-day follow-up period, clinical evidence of organ dysfunction (daily SOFA scores while in the ICU), recovery of renal function, requirement of hemodialysis after day 28 and day 60, duration of renal support, ICU and hospital lengths of stay, and markers of inflammation (interleukin [IL]-6, IL-8, IL-10, IL-18, and macrophage migration inhibitory factor [MIF]).
Blood samples were collected for measurement of inflammatory biomarkers (IL-6, IL-8, IL-10, IL-18 and MIF) on the day of randomization (day 0) and 1 day after randomization (day 1), centrifuged and frozen immediately at −80°C, and then stored until assayed. All inflammatory mediators were analyzed using commercially available assay kits (LEGENDplex; BioLegend).
A group sequential adaptive design with 1 interim analysis and a global (2-sided) significance level α of .05 was used. Power calculations were performed based on the primary end point (ie, the overall mortality in a 90-day follow-up period). The expected 90-day mortality rate in the control group with delayed initiation of RRT was 55% based on the literature.8,11-19 Differences between treatment groups were to be detected with a power of 80%, if the 90-day mortality rate with early initiation of RRT was 37% or less. The expected treatment effect of 18% was calculated on the mortality differences between early and delayed RRT reported in prior studies.8,11-19 A required sample size for the final analysis was 115 patients per treatment group, 230 patients in total. One interim analysis was performed after half of the total number of deaths across both treatment groups. Power calculations were performed based on a 2-sided inverse normal log-rank test,20 using ADDPLAN software (ICON).
Statistical analyses were performed according to the principles of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use guideline E9 using the SAS software for Windows (SAS Institute), version 9.4. Descriptive analyses were performed on all baseline variables including means and standard deviations, medians and quartiles (quartile 1 [Q1], quartile 3 [Q3]), or frequency and percentages, as appropriate. The primary efficacy analysis includes all randomized patients (full analysis set) and was performed according to the intention-to-treat principle (ie, all patients were analyzed in the group to which they were randomized). Patients who received RRT were analyzed in the per-protocol analysis. A group sequential plan according to O’Brien and Fleming with 1 interim analysis was established. To maintain a global significance level α of .05, the interim and the final analysis were performed on local significance levels 0.0052 and 0.0480, respectively. Based on the group sequential plan, in the interim analysis the number of deaths up to the final analysis was recalculated applying the inverse normal method.21 The effect of early vs delayed initiation of RRT on overall mortality in a 90-day follow-up period was assessed by comparing the randomized groups with a (2-sided) inverse normal log-rank test.20 The inverse normal log-rank test is performed by computing P values for the interim and final log-rank tests separately, and then combining these P values so that the overall type I error is controlled. The primary intention-to-treat analysis of the primary outcome provides confirmatory statistical evidence.
The primary statistical analysis was performed first using a hierarchical testing procedure. After reaching a significant result in the primary analysis, each of the secondary outcomes were tested separately using a significance level of .05. No adjustment for multiplicity was applied across the secondary outcomes. Therefore, the results of secondary outcome analyses do not claim confirmatory statistical evidence. The evidence level of the results, however, is more than exploratory, due to the prespecification of secondary outcomes in the protocol, as well as the hierarchical ordering (ie, a required significant result in the primary statistical analysis before the secondary outcomes were tested).
Inferential statistical analyses of time-to-event outcomes that include censored cases were performed using survival analytic methods, such as Kaplan-Meier estimation of the survival function and the log-rank test. Proportional hazards models were fitted after checking the proportionality assumption using the Grambsch and Therneau test, and hazard ratios (HRs) with associated 95% confidence intervals were calculated.
Binary data were tested for significance using the χ2 test or Fisher exact test where appropriate. Event rates were compared by calculating the odds ratio [OR] and absolute risk reduction with associated asymptotic 95% confidence intervals. Normally distributed data were tested for significance using t tests. For non-normal data the Mann-Whitney U test was applied, and median values were compared using the Hodges-Lehmann estimation of location shift with associated 95% confidence interval.
All patients completed 90-day follow up (with a tolerance of ±14 days) and vital status was determined. Therefore, in all corresponding statistical analyses (including the primary analysis) an issue of missing data does not arise. In all other statistical analyses, very little missing occurred and were not replaced using any kind of imputation.
Of 604 patients with AKI screened for the trial, 231 were enrolled and randomized to receive either early initiation of RRT (early group; n = 112) or delayed initiation of RRT (delayed group; n = 119) and included in the primary analysis (Figure 1). The baseline characteristics are shown in Table 1. Baseline NGAL values were not significantly different between both groups (Table 1). There were no significant differences regarding the criteria for dialysis initiation between both groups (eTable 1 in Supplement 2).
All 112 patients assigned to early group received RRT. However, for the 119 participants assigned to delayed group, only 108 received RRT. RRT was not initiated in 11 patients (9.2%) because 6 patients (5.0%) did not progress to severe AKI (stage 3), 4 patients had protocol violations (3.4%; the patients recovered renal function after reaching stage 3 but without RRT), and 1 patient (0.8%) had no RRT device available. Consistent with the protocol, absolute indications occurred in 18 patients in the delayed group (15.1%), 17 of whom received RRT before reaching KDIGO stage 3 criteria. At randomization, serum creatinine and urine output were not significantly different between early and delayed groups (mean [SD] serum creatinine, 1.95 mg/dL [0.64] for the early group vs 2.00 mg/dL [1.1] for the delayed group, P = .67; median [Q1, Q3] urine output, 460 mL/24 h [187.5, 840.0] for the early group vs 500 mL/24 h [156.3, 1042.0] for the delayed group, P = .89). The median time from meeting full eligibility criteria to RRT initiation in the early group (6.0 hours [Q1, Q3: 4.0, 7.0]) was significantly shorter compared with the delayed group (25.5 hours [Q1, Q3: 18.8, 40.3]; between-group difference, −21.0 [95% CI, −24.0 to −18.0]; P < .001; Table 2). In addition, patients in the delayed group were analyzed separately. The median time from randomization to initiation of RRT was similar in those patients reaching KDIGO stage 3 compared with the patients developing an absolute indication (25 hours [Q1, Q3: 19, 40] for patients reaching KDIGO stage 3 vs 27 hours [Q1, Q3: 14, 41] for patients with an absolute indication, P = .97). At the time of RRT initiation, serum creatinine and urea concentrations were both higher in the delayed group compared with the early group, whereas urine output was significantly lower in the delayed group compared with the early group (Table 2). All other clinical and biochemical parameters were similar at the time of RRT initiation (Table 2).
Early initiation of RRT significantly reduced 90-day mortality (Figure 2) compared with delayed initiation of RRT (44 of 112 patients [39.3%] in the early group vs 65 of 119 patients [54.7%] in the delayed group; P = .03; HR, 0.66 [95% CI, 0.45 to 0.97]; between-group difference, −15.4% [95% CI, −28.1% to −2.6%]) (Table 3). A subgroup analysis of patients randomized to delayed initiation of RRT found no significant difference between those reaching stage 3 and those developing an absolute indication of RRT for the primary end point (eTable 2 in Supplement 2).
Early initiation of RRT significantly reduced the median duration of RRT compared with the delayed group (9 days [Q1, Q3: 4, 44] for the early group vs 25 days [Q1, Q3: 7, >90] for the delayed group, P = .04; HR, 0.69 [95% CI, 0.48 to 1.00]; between-group difference, −18 [95% CI, −41 to 4]), enhanced recovery of renal function at day 90 (60 of 112 patients [53.6%] for the early group vs 46 of 119 patients [38.7%] for the delayed group, P = .02; OR, 0.55 [95% CI, 0.32 to 0.93]; between-group difference, 14.9% [95% CI, 2.2% to 27.6%]), reduced the median duration of mechanical ventilation (125.5 hours [Q1, Q3: 41, 203] for the early group vs 181.0 days [Q1, Q3: 65, 413] for the delayed group, P = .002; between-group difference, −60 [95% CI, −110.0 to −22.0]), and decreased the length of hospital stay (51 days [Q1, Q3: 31, 74] for the early group vs 82 days [Q1, Q3: 67, >90] for the delayed group, P < .001; HR, 0.34 [95% CI, 0.22 to 0.52]; between-group difference, −37 [95% CI, −∞ to −19.5]). However, no significant differences between the 2 groups were seen in the requirement of RRT on day 90 (9 of 67 patients [13.4%] for the early group vs 8 of 53 patients [15.1%] for the delayed group; OR, 0.87 [95% CI, 0.31 to 2.44]; between-group difference, −1,7% [95% CI, −14.3% to 11.0%], P = .80) and in the length of ICU stay were found (19 days [Q1, Q3: 9, 29] in the early group vs 22 days [Q1, Q3: 12, 36] in the delayed group, P = .33; HR, 0.85 [95% CI, 0.61 to 1.19]; between-group difference, −3.0 [95% CI, −12.0 to 4.5]) (Table 3).
Subgroup analysis of patients randomized to the delayed treatment group comparing those reaching stage 3 vs those developing an absolute indication for RRT found no significant differences for the secondary end points of duration of RRT, ICU, and hospital stay (eTable 2 in Supplement 2).
There were no significant differences regarding RRT modalities (blood flow per session, effluent volume per session, and session duration) between the groups (eTable 3 in Supplement 2). Not considering death, 1 serious adverse event (new-onset arrhythmia) and 84 adverse events among 112 patients in the early group were observed, and no serious adverse events and 74 adverse events in 108 patients were observed in the delayed RRT group (eTable 3 in Supplement 2). RRT-related complications were similar in both treatment groups (eTable 3 in Supplement 2). In total, 32 of 112 patients (28.6%) in the early group vs 42 of 108 patients (38.9%) in the delayed group were transitioned to other RRT modalities after receiving continuous RRT: 25 of 112 patients (22.3%) in the early group vs 32 of 108 patients (29.6%) in the delayed group were transitioned to SLEDD, 2 of 112 patients (1.8%) in the early group vs 2 of 108 patients (1.9%) in the delayed group were transitioned to intermittent hemodialysis, and 5 of 112 patients (4.5%) in the early group vs 8 of 108 patients (7.4%) in the delayed group were transitioned to SLEDD and then to intermittent hemodialysis before being discharged (eTable 3 in Supplement 2). Daily fluid balance between early and delayed groups did not differ within the first 3 days after randomization (median [Q1, Q3]: day one, 2773 mL [702, 5280] for the early group vs 2207 mL [441, 4167] for the delayed group, P = .15; day two, 1102 mL [−493, 2789] for the early group vs 1077 mL [−80, 2465] for the delayed group, P = .79; day three, 384 mL [−913, 1847] for the early group vs 209 mL [−933, 1428] for the delayed group, P = .41).
Pro- (MIF, IL-6, IL-8, and IL-18) and anti-inflammatory (IL-10) cytokine concentrations in the blood were measured. These molecules were selected because they are involved in inflammation and have been associated with decreased survival and recovery in prior studies.22-25 At the time of randomization, the plasma concentrations of biomarkers MIF, IL-6, IL-8, IL-10, and IL-18 did not differ between groups (eTable 4 in Supplement 2). Twenty-four hours after randomization when 100% patients in the early group and 21.8% of patients in the delayed group had received at least 6 hours of RRT, IL-6 and IL-8 concentrations were significantly reduced in the early group compared with the delayed group (IL-6: 399.4 pg/mL in the early group vs 989.3 pg/mL in the delayed group; Hodges-Lehmann estimation of location shift, 310.9 [95% CI, 93.3-663.2]; P = .02; IL-8: 65.7 pg/mL for the early group vs 215.5 pg/mL for the delayed group; Hodges-Lehmann estimation of location shift, 105.9 [95% CI, 52.7-160.6]; P = .001), whereas the plasma concentrations of MIF, IL-10, and IL-18 did not differ between groups (eTable 4 in Supplement 2). Furthermore, by Cox regression analysis, IL-6 and IL-8 at day 1 were associated with mortality (eTable 5 in Supplement 2).
Quiz Ref IDIn this randomized clinical trial of critically ill patients with AKI, the use of early RRT compared with delayed therapy reduced mortality over the first 90 days and reduced duration of RRT and length of hospital stay.
Three other trials have evaluated outcomes following early vs delayed initiation of RRT.8-10 In a randomized clinical trial, Bouman and colleagues8 enrolled 106 patients with AKI and randomized them to early or delayed RRT initiation. Patients in the early group received RRT soon after meeting criteria for AKI, whereas delayed initiation of RRT was defined when patients developed hyperkalemia or pulmonary edema or had plasma urea levels higher than 440 mmol/L. There was no difference in mortality. One important limitation of this study was that patients who were intended to receive RRT early (early group) received RRT rather late in the course of AKI. Another single-center trial performed in India enrolled 208 patients with community-acquired AKI.9 In the early group, RRT was started after serum creatinine exceeded 7 mg/dL or serum urea exceeded 25 mmol/L regardless of other AKI complications. In the usual care group, RRT was initiated only in the setting of refractory hyperkalemia, acidosis, or volume overload or if uremic symptoms developed. No differences in kidney recovery or mortality were observed. In line with these results, a recently published multicenter trial investigating accelerated vs standard initiation of RRT in 101 critically ill patients with AKI also demonstrated no mortality difference between both groups.10 However, this was a feasibility trial, and the trial was not powered to investigate mortality. Finally, 1 small randomized clinical trial demonstrated that early initiation of RRT was associated with a reduced mortality compared with late initiation of RRT.18 In this study, the authors evaluated the role of early RRT in 28 patients with AKI following cardiac surgery. Fourteen patients were started on continuous hemodialysis when their urine volume decreased to less than 30 mL/h for 3 hours. In patients in the “late” group (n = 14), RRT was delayed until urine output had fallen to less than 20 mL/h for 2 hours. Survival was significantly better in the group of patients who started RRT earlier. There were no differences between the 2 groups with respect to age, sex, Acute Physiology and Chronic Health Evaluation (APACHE) II score, and serum creatinine level at the time of initiation of RRT.
The results of a recently published meta-analysis suggest that earlier initiation of RRT in critically ill patients with AKI may have beneficial association with survival (OR, 0.45 [95% CI, 0.28-0.72]).7 However, this conclusion is based on heterogeneous studies of variable quality. Therefore, more randomized trials are required to answer this question. This research priority has been articulated by the KDIGO clinical practice guidelines,5 and the Acute Kidney Injury Network26 has prioritized this research topic.
Quiz Ref IDPotential benefits of earlier initiation are attributable to more rapid metabolic or uremic control and more effective prevention and management of fluid overload.27 Some data also suggest that RRT before the onset of severe AKI may attenuate kidney-specific and non–kidney organ injury from acidemia, uremia, fluid overload, and systemic inflammation and could potentially translate into improved survival and earlier recovery of kidney function.28,29 The counterargument is that a strategy of early initiation of RRT might subject patients who would recover renal function with conservative treatment alone to the potential risks associated with RRT. However, AKI confers a substantial increased risk of death even in patients never treated with RRT.30 As such, although there may be a risk of “unnecessary” RRT, there could be an even greater risk associated with not providing it. To avoid treating patients with RRT who may have otherwise spontaneously recovered kidney function, biomarkers in addition to the KDIGO classification system were used in this trial because it has been demonstrated that plasma NGAL is a good predictor for the need of RRT in critically ill patients with AKI.31,32 Moreover, NGAL concentration can be measured at the bedside within 20 minutes, making this biomarker suitable for a trial testing a time-sensitive intervention. Our data demonstrate that the combination of the KDIGO classification system in combination with plasma NGAL can reliably detect patients with progressively deteriorating AKI. Only 5% (6 of 119 patients) of the patients in the delayed group did not receive RRT, because they spontaneously recovered or died.
Fluid accumulation in patients with AKI is associated with adverse outcomes.33 However, in our study we could exclude that fluid accumulation was responsible for a worse outcome in the delayed group because there were no differences in daily fluid balance before and within 3 days after randomization. As some data suggest that initiation of RRT before the onset of severe AKI may attenuate kidney-specific and non–kidney organ injury from systemic inflammation.28,29 It is possible that the reduced plasma levels of inflammatory mediators in the early group are responsible for the reduced mortality. Our data extend the findings of other studies in which pro-inflammatory cytokines were associated with poorer outcomes.22,34,35 Increased IL-8 concentrations are associated with an increased risk of RRT dependence and death.36 IL-8, a chemokine, is an important mediator of innate and adaptive immunity and has been implicated in the pathogenesis of AKI.37-39 Higher IL-8 concentrations may reflect a persistent pro-inflammatory milieu among renal tubular cells impairing renal recovery. IL-6 is a pleiotropic cytokine and higher concentrations have been associated with increased susceptibility to AKI40 and mortality in patients with AKI.22
As several molecules were associated with adverse outcomes in our study, immunomodulation strategies that include inhibition of single molecules are unlikely to be successful, and broad-spectrum modulation of multiple molecules may be needed to improve outcomes in AKI patients.
Quiz Ref IDStudy limitations need to be considered. Although a large mortality difference was detected, this was not a multicenter trial, and as with many single-center studies, the observed effect size is likely inflated. Furthermore, larger trials are needed because small trials cannot avoid small baseline differences. Another limitation of this study is the limited generalizability, because almost all patients recruited were surgical patients. Our study provides important feasibility data for an AKI stage-based, biomarker-guided interventional trial in AKI. However, an adequately powered multicenter trial is needed to confirm our results and establish the best time point for the initiation of RRT in critically ill patients with AKI.
Among critically ill patients with AKI, early RRT compared with delayed initiation of RRT reduced mortality over the first 90 days. Further multicenter trials of this intervention are warranted.
Corresponding Author: Alexander Zarbock, MD, Department of Anesthesiology, Critical Care Medicine and Pain Therapy, University Hospital Münster, Albert-Schweitzer-Campus 1, Gebäude A1, 48149 Münster, Germany (email@example.com).
Correction: This article was corrected for errors in the text on August 23, 2016.
Published Online: May 22, 2016. doi:10.1001/jama.2016.5828.
Author Contributions: Drs Zarbock and Meersch had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: Zarbock, Kellum, Aken, Wempe, Pavenstädt, Gerß, Meersch.
Acquisition, analysis, or interpretation of data: Zarbock, Kellum, Schmidt, Boanta, Gerß, Meersch.
Drafting of the manuscript: Zarbock, Wempe, Pavenstädt, Gerß, Meersch.
Critical revision of the manuscript for important intellectual content: Zarbock, Kellum, Schmidt, Aken, Boanta, Gerß, Meersch.
Statistical analysis: Gerß, Meersch.
Obtained funding: Zarbock.
Administrative, technical, or material support: Zarbock, Schmidt, Aken, Wempe, Boanta, Meersch.
Study supervision: Zarbock, Aken, Pavenstädt, Meersch.
Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported. Dr Zarbock reports receiving grant support and lecture fees from Astute Medical. Dr Kellum reports receiving grant support and consulting fees from Astute Medical, Alere, and Baxter. No other disclosures were reported.
Funding/Support: The study was funded by the Else-Kröner Fresenius Stiftung (2013_A46 to A.Z.).
Role of the Funder/Sponsor: The study sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Create a personal account or sign in to: